U.S. Paper and Forestry Products Stock News

NYSE:DVA
NYSE:DVAHealthcare

DaVita (DVA) Earnings Put Its Valuation Back In Focus

DaVita earnings event and why it matters for shareholders DaVita (DVA) just released second quarter 2026 results, with revenue of US$3.55b and net income of US$265.4m, giving investors fresh numbers on profitability and overall business performance. See our latest analysis for DaVita. DaVita’s latest earnings arrive after a strong run in the stock, with the share price at US$227.99 and a year to date share price return of 99.1%. Momentum has cooled in the very short term, with the 7 day share...
NasdaqGS:KHC
NasdaqGS:KHCFood

Kraft Heinz (KHC) Reports Another Net Loss, Is It Still Below Fair Value?

Kraft Heinz (KHC) recently reported second quarter results that included a continued net loss and large impairment charges, while also affirming a regular quarterly dividend. These moves give investors fresh data on earnings quality and capital returns. See our latest analysis for Kraft Heinz. Kraft Heinz shares have a 90 day share price return of 15.47% and a 30 day share price return of 5.01%. However, the 5 year total shareholder return of an 8.92% decline shows longer term momentum has...
NYSE:VIK
NYSE:VIKHospitality

Viking Holdings (VIK) Expands Its Fleet After Viking Dagur Delivery But Is The Stock Fully Valued

Viking Holdings (VIK) is back in focus after the company took delivery of its newest 190 guest longship, Viking Dagur, and outlined a sizeable expansion of its river, ocean and expedition fleets. See our latest analysis for Viking Holdings. Alongside this fleet expansion story, Viking Holdings has also seen strong momentum in its stock. The 30 day share price return is 6.78% and the 90 day share price return is 24.95%, while the 1 year total shareholder return stands at 84.71%. This suggests...
NYSE:SSB
NYSE:SSBBanks

How SouthState’s Q2 Earnings Beat, Dividend Hike and Buybacks Will Impact SouthState Bank (SSB) Investors

In July 2026, SouthState Bank Corporation reported second-quarter results showing net interest income of US$575.95 million, net income of US$230.02 million, net charge-offs of US$8 million (0.06% of average loans), a completed US$247.6 million share repurchase program, and a quarterly dividend increase from US$0.60 to US$0.66 per share, payable August 14, 2026. Together, higher earnings, very low net charge-offs, a larger dividend, and completed buybacks point to management’s confidence in...
NasdaqGS:GEN
NasdaqGS:GENSoftware

Does Gen Digital’s New Fearless Planet Index Reframe Its Cyber Data Edge For Investors (GEN)?

Gen Digital recently launched the Fearless Planet Index, a continuously updated cyber safety intelligence hub that uses Gen Threat Labs telemetry to map real-time scams, malware and identity risks across 245 countries and territories. Early Fearless Planet Index insights show phishing dominating global scam activity and reveal sharp country-level differences, giving consumers a localized view of fast-shifting digital risks. With this new real-time Fearless Planet Index showcasing Gen...
NYSE:BWA
NYSE:BWAAuto Components

Lear Stock And 2 Auto Suppliers With Tariff Refund Exposure In Focus

Tariff policy is back in the spotlight after court rulings, refunds and fresh import charges have reshaped the cost of bringing goods into the US. For import heavy stocks, the mix of a US$100b refund pool, legal challenges and new tariffs on more than 80 countries creates both relief and fresh risk. Some companies may gain breathing room from extra liquidity, while others face higher input costs and policy uncertainty. This article looks at 3 stocks exposed to these trade developments and how...
NasdaqGS:FSLY
NasdaqGS:FSLYIT

Fastly (FSLY) Could Be 402% Overvalued As Experian Partnership Lifts AI Commerce Narrative

Fastly (FSLY) stock is back in focus after the company joined Experian's Agent Trust ecosystem, a collaboration aimed at securing AI driven commerce by verifying AI agents and authorizing their transactions at the network edge. See our latest analysis for Fastly. The Experian partnership arrives at a time when Fastly's share price has gained strong short term momentum, with a 1 day share price return of 8.34%, a 7 day return of 19.95% and a 30 day return of 37.62%. However, the 90 day return...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

DexCom (DXCM) Raised Full Year Guidance, Is The Upside Already Priced In?

DexCom (DXCM) drew fresh attention after reporting second quarter 2026 results with higher sales and earnings, and raised full year revenue guidance to a range of about US$5.18b to US$5.25b. See our latest analysis for DexCom. DexCom shares have moved sharply higher in recent weeks, with a 7 day share price return of 16.15% and a 90 day share price return of 44.04%. The 1 year total shareholder return of 15.21% contrasts with weaker 3 and 5 year total shareholder returns. This suggests recent...
NasdaqGS:OPRA
NasdaqGS:OPRASoftware

Opera (OPRA) Is Up 9.4% After $300M Buyback And Stronger ARPU – Has The Bull Case Changed?

In early August 2026, Opera Limited reported 288 million monthly active users for the first quarter, a 25% increase in annualized average revenue per user, and authorized a US$300,000,000 share repurchase program while scheduling its second-quarter 2026 earnings release and call for August 25, 2026. The combination of rising user monetization, expanding AI-powered browser features, and a substantial buyback authorization underscores Opera’s confidence in its business model and capital...
NYSE:FBIN
NYSE:FBINBuilding

Should Fortune Brands Innovations’ Upgraded Profit Outlook and EPS Beat Require Action From FBIN Investors?

Fortune Brands Innovations recently reported June-quarter results showing non-GAAP earnings per share well above analyst expectations, while revenue came in slightly below consensus amid a low single-digit sales decline. The company also raised its full-year 2026 earnings and operating margin guidance, signaling management’s confidence in improving profitability despite softer top-line trends and a recent senior legal leadership change. With full-year earnings guidance now higher, we'll...
NYSE:AGO
NYSE:AGOInsurance

Should Assured Guaranty’s (AGO) Q2 Earnings Miss Versus Expectations Require Action From Investors?

On 6 August 2026, Assured Guaranty Ltd. reported its second-quarter results, with Wall Street having expected consensus earnings of US$1.56 per share, materially above the US$1.01 delivered in the same quarter a year earlier. With investors closely watching loss reserve development, municipal finance business trends, and insured portfolio credit quality, this earnings release highlighted how core underwriting fundamentals may influence how the company is viewed ahead of 2029 analyst...
NYSE:IMAX
NYSE:IMAXEntertainment

IMAX (IMAX) Stock Still Looks Below Fair Value Despite Rich Earnings

IMAX stock has delivered very strong gains over the past five years, yet its valuation signals now point in different directions, with a Discounted Cash Flow (DCF) intrinsic value estimate suggesting meaningful upside while earnings based multiples look stretched. That split leaves investors weighing a powerful share price run against mixed signals on what the stock might be worth today. IMAX has returned 252.1% over the past five years. This places recent price moves firmly in the context...
NasdaqGS:KSPI
NasdaqGS:KSPIConsumer Finance

Spotify Stock Leads 3 Founder Led Digital Growth Names Worth Research

Founder led companies can give you something that is hard to measure but easy to value: leaders with skin in the game who are building long term legacies rather than chasing the next quarter. With global growth signals improving in several developed markets, inflation generally easing in key regions and central banks moving toward steadier policy paths, many investors are looking for management teams that stay focused through economic cycles. This Founder Led Companies screener narrows that...
NasdaqGM:ZLAB
NasdaqGM:ZLABBiotechs

Does New US Orphan Drug Status For Zoci Reshape The Bull Case For Zai Lab (ZLAB)?

Zai Lab recently reported that the U.S. FDA granted Orphan Drug Designation to its DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan (Zoci), for treating neuroendocrine carcinomas, a group of aggressive cancers with limited options. This second orphan designation, following a similar decision in Europe, underlines Zoci’s potential as a first-in-class therapy in a difficult tumor type. We’ll now examine how this new Orphan Drug Designation for Zoci could influence Zai Lab’s...
NasdaqGM:FIVN
NasdaqGM:FIVNSoftware

Alphabet Stock Falls as AI Shakeup Puts Five9 Intel and CEVA in Focus

Alphabet’s surprise AI shakeup has put fresh attention on where leadership and talent sit inside the sector. Jeff Dean and Sanjay Ghemawat are leaving Google to launch a new AI company backed by Alphabet. Demis Hassabis is moving into a chairman and chief scientist role, and Koray Kavukcuoglu is stepping up to run Google’s AI unit and oversee Gemini 4. Alphabet stock fell about 4% after the news. For investors, that kind of disruption can reshape expectations. This article walks through 3 AI...
NYSE:BETA
NYSE:BETAAerospace & Defense

Can BETA Technologies (BETA) Justify Its Valuation Following Up To $1b In EXIM Financing?

BETA Technologies (BETA) drew fresh investor attention after announcing plans to expand its financing relationship with the Export Import Bank of the United States, with the potential to secure up to $1b in net funding. See our latest analysis for BETA Technologies. The EXIM financing headlines come after a sharp shift in sentiment around BETA Technologies, with the 1 day share price return of 13.2% and 7 day share price return of 19.5% contrasting with a year to date share price return that...
NasdaqGM:SYM
NasdaqGM:SYMMachinery

Symbotic (SYM) Heads Into Earnings With A Growth Narrative And Undervalued View

Symbotic (SYM) heads into its upcoming quarterly earnings report with investor attention on expectations for $0.12 in earnings per share and US$714.76 million in revenue, alongside forecast growth across key warehouse automation segments. See our latest analysis for Symbotic. At a share price of US$47.46, Symbotic has seen a 17.65% 7 day share price return but remains down 26.84% year to date, while the 5 year total shareholder return is about 4x. This indicates short term volatility...
NYSE:CVX
NYSE:CVXOil and Gas

Chevron (CVX) Posts Blowout Q2 Earnings, Is The 12% Undervaluation Case Convincing?

Chemron (CVX) is back in focus after reporting second quarter 2026 results that materially reshaped its income statement. Revenue reached US$70.1b, net income was US$12.1b, and diluted EPS from continuing operations was US$6.11. See our latest analysis for Chevron. Chemron's share price has reacted strongly to the Q2 earnings and dividend news, with a 30 day share price return of 12.53% and a year to date share price return of 22.13%. Over the past year, total shareholder return of 29.62% and...
NasdaqGS:TYRA
NasdaqGS:TYRABiotechs

Tyra Biosciences (TYRA) Reports Q2 Results, Is The Pipeline Potential Already Priced In?

Why Tyra Biosciences Stock Is Back in Focus After Q2 Results Tyra Biosciences (TYRA) moved into the spotlight after reporting second quarter 2026 results, with a wider net loss and updated timelines for key clinical readouts that could influence how investors view its development pipeline. See our latest analysis for Tyra Biosciences. The second quarter update has arrived during a period where Tyra Biosciences has experienced firm share price momentum, with a 1-month share price return of...
NasdaqGS:KDP
NasdaqGS:KDPBeverage

Should JDE Peet’s Integration and Refreshment Growth Expectations Require Action From Keurig Dr Pepper (KDP) Investors?

In early August 2026, Keurig Dr Pepper was expected by Wall Street analysts to report past-quarter earnings of US$0.55 per share and revenue of US$7.17 billion, with forecasts also highlighting growth in U.S. Refreshment Beverages and international sales. Analysts also pointed to the integration of the recently acquired JDE Peet's business as a key factor, with potential synergies and international expansion efforts seen as important supports for the company’s performance amid inflation and...
NYSE:CI
NYSE:CIHealthcare

Why Cigna Group (CI) Is Down 9.0% After Strong Q2 Results Meet PBM and Regulatory Jitters

The Cigna Group reported its second-quarter 2026 results, with revenue rising to US$71.67 billion and net income to US$1.66 billion, alongside continued share repurchases under its multiyear buyback program. Despite this growth, recent analyst downgrades have drawn attention to regulatory pressures and uncertainty around Cigna’s pharmacy benefit management operations and business portfolio review. Next, we’ll examine how solid quarterly earnings but heightened PBM and regulatory concerns may...
NYSE:TUYA
NYSE:TUYASoftware

Did Tuya’s (TUYA) No-Code AI Platform Just Redefine Its AI-Driven IoT Investment Narrative?

Tuya Smart recently launched Tuya AI Coding, an AI-native no-code platform that lets non-technical users create and deploy AI-powered lifestyle applications via simple natural-language prompts, fully integrated with Tuya’s global AI+IoT stack and device ecosystem. The ability for Tuya AI Coding to auto-generate full back-end architectures and connect apps to more than 100,000 supported devices could significantly deepen engagement across Tuya’s AI Home ecosystem. Next, we’ll examine how Tuya...
NYSE:TYL
NYSE:TYLSoftware

Tyler Technologies (TYL) Lands Tennessee Statewide Cloud Tax Migration

Tennessee completed a statewide cloud migration of its Enterprise Assessment & Tax solution with Tyler Technologies (NYSE:TYL). The project supports nearly 800 users in the Comptroller of the Treasury, Division of Property Assessments. The deployment runs on Amazon Web Services infrastructure and is focused on long term SaaS delivery. The transition is described as one of the largest and most significant statewide cloud moves for this type of system. This Tennessee project places Tyler...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates

Summit Therapeutics (SMMT) is back in focus after expanding its ivonescimab program with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration with Arcus Biosciences. See our latest analysis for Summit Therapeutics. The latest ivonescimab updates come after a period where Summit Therapeutics’ share price has been volatile. The 1-year total shareholder return declined 51.75%, and the 3-year total shareholder return was very...